Busque 2001.

Methods	Study type: parallel RCT Study time frame/year of transplantation: not reported Duration of follow‐up: 6 months
Participants	Country: Canada Setting: multicentre (6) Adult recipients receiving their first cadaveric kidney transplant Deceased donor: 100% previous transplantation: 0% PRA level: not reported HLA mismatch (median): 3 Cold ischaemia time (mean): 15 h Delayed graft function: 22% Number: treatment group (23); control group (23) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group MMF 2 g/d, orally Control group AZA 1.5 to 2 mg/kg body weight/d, orally Concomitant immunosuppression Induction antibody: agent unclear, if delayed graft function Tac target C0 (month 3): 5 to 15 ng/mL Corticosteroids
Outcomes	Death Graft loss Primary non‐function Acute rejection NODAT Kidney function measures (SCr)
Notes	Additional intervention arm (CsA/MMF) Publication: Transplantation Proceedings Language: English
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information about the sequence generation process to permit judgment
Allocation concealment (selection bias)	Unclear risk	Randomisation stated, but no information on allocation method used is available
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgment
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT analysis unclear; number randomised or number of patients at the end of the study was not reported
Selective reporting (reporting bias)	Low risk	The published report included most expected outcomes regarding efficacy and safety
Other bias	High risk	The study was supported by Fujisawa Canada Inc.